Caribou Biosciences (NASDAQ:CRBU) Announces Earnings Results, Beats Expectations By $0.01 EPS

Posted by James Quigley on Mar 10th, 2025

Caribou Biosciences (NASDAQ:CRBU – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01, Zacks reports. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%.

Caribou Biosciences Stock Down 4.7 %

CRBU stock traded down $0.06 on Monday, reaching $1.11. 859,808 shares of the company’s stock were exchanged, compared to its average volume of 1,655,743. Caribou Biosciences has a twelve month low of $1.01 and a twelve month high of $7.61. The stock has a fifty day moving average of $1.43 and a 200-day moving average of $1.81. The firm has a market cap of $100.06 million, a PE ratio of -0.67 and a beta of 2.34.

Analysts Set New Price Targets

CRBU has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Bank of America cut their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Citigroup lowered their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $10.33.

Read Our Latest Stock Report on CRBU

About Caribou Biosciences

(Get Free Report)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.